IL2 and type 1 diabetes mellitus: Indeed, clinical studies in patients with T1D and in patients after liver transplantation have shown that systemic low-dose administration of IL-2 can lead to off-target adverse complications manifested by a decrease in C-peptide (7) or TH1 activation (EudraCT #2017-000177-37), resulting in graft rejection.